LigaChem Biosciences Inc.
Financials
Valuation Metrics
LigaChem Biosciences Inc.'s Market Cap is ₩2.3T. At end of 2025 it was ₩6.4T. Ranked #166 of 2,410 in KR market (top 7%), #22 of 1,631 on KOSDAQ (top 1%), #10 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 4%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 2.28T KRW | KR#166/2,410 Sec#10/231 |
| Revenue | 98.78B KRW | KR#1,426/2,410 Sec#88/231 |
| Net Income | -181.37B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 701.81B KRW | KR#610/2,410 Sec#34/231 |
| Net Assets | 541.12B KRW | KR#482/2,410 Sec#30/231 |
| Employees | 174 | KR#1,194/2,410 Sec#99/231 |
| Value | ||
| P/B | 4.22x | KR#2,224/2,410 Sec#191/231 |
| P/S | 23.13x | KR#2,340/2,410 Sec#188/231 |
| FCF Yield | -5.58% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -33.52% | KR#2,204/2,410 Sec#184/231 |
| ROA | -25.84% | KR#2,276/2,410 Sec#191/231 |
| Op. Margin | -208.25% | KR#2,325/2,410 Sec#185/231 |
| Revenue Growth | -33.38% | KR#2,227/2,410 Sec#199/231 |
| Financial Health | ||
| Debt Ratio | 29.70% | KR#583/2,410 Sec#66/231 |
| Total Debt | 0 KRW | KR—/2,410 Sec—/231 |
| FCF | -127.58B KRW | KR#2,142/2,410 Sec#212/231 |
| Cash | 98.65B KRW | KR#474/2,410 Sec#23/231 |
| Current Ratio | 9.37x | KR#111/2,410 Sec#27/231 |
| Performance | ||
| 1Y Return | -57.86% | KR#2,097/2,410 Sec#194/231 |
| 1M Return | -25.03% | KR#2,075/2,410 Sec#209/231 |
| From 52W High | -72.58% | KR#2,125/2,410 Sec#185/231 |
| 1Y MDD | -71.19% | KR#2,013/2,410 Sec#173/231 |
| Trading | ||
| Volume | 103,404 shares | KR#636/2,410 Sec#67/231 |
| Trading Value | 6.37B KRW | KR#246/2,410 Sec#19/231 |
| Foreign Own. | 12.63% | KR#391/2,410 Sec#28/231 |
| Per Share | ||
| EPS | -4,897 KRW | KR—/2,410 Sec—/231 |
| BPS | 14,612 KRW | KR#717/2,410 Sec#46/231 |
Company Info
LegoChem Biosciences, established in 2006 and headquartered in Yuseong-gu, Daejeon, is a research-oriented pharmaceutical company listed on KOSDAQ in 2013. The company developed the medicinal chemistry-based original Antibody-Drug Conjugate (ADC) technology named ConjuALL, driving global commercialization through ADC anticancer drug research and development and technology transfer. Through "Beyond ADC" research, it focuses on developing bispecific antibody ADCs, immuno-oncology drugs, and combination therapies, while also securing stable revenue from medical device and consumable sales.